Egrifta (Tesamorelin) Storage, Stability & Shelf Life

What Is Tesamorelin and How Does Egrifta Work?

Tesamorelin is a synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile growth hormone (GH) secretion, which in turn raises insulin-like growth factor 1 (IGF-1) and drives lipolysis in visceral adipose tissue. The net clinical effect is a measurable reduction in the excess trunk fat seen in HIV-associated lipodystrophy.

Mechanism at the Receptor Level

Endogenous GHRH is a 44-amino-acid peptide. Tesamorelin is a 44-amino-acid GHRH(1-44) analogue conjugated to a trans-3-hexenoic acid group at the N-terminus. That modification extends the half-life relative to native GHRH by reducing dipeptidyl peptidase IV (DPP-IV) cleavage [1]. Binding to the pituitary GHRH receptor activates adenylyl cyclase, raises intracellular cAMP, and triggers GH exocytosis in a pulse pattern that preserves the physiologic feedback axis.

Because tesamorelin amplifies endogenous GH secretion rather than replacing GH entirely, the hypothalamic-pituitary-IGF-1 feedback loop remains intact [2]. Serum IGF-1 rises by roughly 181 ng/mL above baseline in treated HIV patients, but the diurnal pulsatility of GH is preserved, which is thought to reduce the adverse-effect burden compared with exogenous recombinant human GH.

Downstream Lipolytic Effects

Elevated GH promotes adipocyte triglyceride hydrolysis via hormone-sensitive lipase. Visceral adipocytes express more GH receptors per cell than subcutaneous adipocytes, explaining why tesamorelin preferentially reduces visceral rather than subcutaneous fat [3]. The FDA-approved label notes a mean visceral adipose tissue (VAT) reduction of approximately 15% at 26 weeks, a figure independently confirmed in the key Falutz et al. Trial published in the New England Journal of Medicine [4].

Egrifta Storage Requirements: Unreconstituted Vials

Keep unreconstituted Egrifta vials refrigerated between 2°C and 8°C (36°F to 46°F) at all times before use [5]. The lyophilized powder is sensitive to both heat and photodegradation, so vials must be stored in the original carton to shield them from light.

Temperature Excursions

Brief excursions outside the 2 to 8°C range can occur during transport. The FDA-approved prescribing information (PI) does not specify a validated out-of-refrigerator window for the lyophilized powder, which means any temperature excursion of unknown duration should prompt pharmacist or manufacturer consultation before use [5]. Temperatures above 25°C accelerate peptide aggregation and deamidation, degradation pathways common to all lyophilized GH-axis peptides [6].

Light Sensitivity

Peptide bonds and aromatic amino acid side chains (phenylalanine, tyrosine) absorb UV and visible light, generating reactive oxygen species that fragment or cross-link the peptide. Store vials in the original carton until the moment of reconstitution [5].

Freezing: A Hard Contraindication

Do not freeze Egrifta. Ice crystal formation during freezing disrupts the lyophilized cake structure and causes irreversible aggregation of the tesamorelin peptide. A frozen-then-thawed vial may appear intact, but peptide potency will be compromised. Discard any vial that has been frozen [5].

Reconstitution: Step-by-Step and Stability Window

Egrifta is supplied as a 2 mg lyophilized powder vial paired with a 2.1 mL vial of sterile water for injection (SWFI). The reconstitution procedure directly affects post-reconstitution stability [5].

Reconstitution Protocol

1. Allow both vials to reach room temperature for approximately 30 minutes before mixing. Injecting a cold solution increases discomfort and may alter peptide solubility.
2. Inject 2.1 mL of SWFI into the tesamorelin powder vial using the supplied needle.
3. Roll the vial gently between your palms for 30 seconds. Do not shake. Vigorous agitation creates air-water interfaces that denature the peptide and generate visible particulates.
4. The resulting solution should be clear and colorless. Discard the vial if the solution appears cloudy, discolored, or contains visible particles [5].
5. Withdraw the full dose and inject subcutaneously into the abdomen. Rotate injection sites to reduce lipohypertrophy at the injection site.

Post-Reconstitution Stability: 3-Hour Window

Once reconstituted, use the solution within 3 hours [5]. Aqueous tesamorelin solutions are susceptible to hydrolysis, deamidation at asparagine residues, and physical aggregation at room temperature. There are no published data supporting refrigerated storage of the reconstituted solution; the prescribing information does not permit it. Discard any unused portion after 3 hours.

The table below summarizes the storage conditions across the product life cycle.

| Stage | Condition | Duration | |---|---|---| | Unreconstituted (refrigerated) | 2 to 8°C, light-protected | Until printed expiry | | Unreconstituted (room temperature) | Not validated; avoid | N/A | | Unreconstituted (frozen) | CONTRAINDICATED | Discard | | Reconstituted at room temperature | Use immediately | Max 3 hours | | Reconstituted (refrigerated) | Not supported by label | Discard |

Shelf Life and Expiry Dating

The printed expiry date on each Egrifta vial reflects Theratechnologies' real-time stability data submitted to the FDA during the new drug application (NDA) review process [5]. Lyophilized peptide shelf life is determined by the rate of moisture uptake, residual water content in the cake, and peptide-specific degradation kinetics at the labeled storage temperature.

Checking the Label Before Each Dose

Patients should inspect the expiry date printed on both the powder vial and the SWFI vial before every injection. Both vials must be within their expiry dates. An expired SWFI vial may show increased particulate burden from leachates, even if the water appears clear.

Impact of Pharmacy Compounding on Stability

Compounded tesamorelin formulations, sourced outside the FDA-approved Egrifta product, are not subject to the same NDA stability-testing requirements. Compounded peptide vials may use different lyophilization parameters, different excipients, and different container-closure systems, all of which alter the stability profile [7]. A 2021 FDA analysis of compounded sterile preparations found that 9 of 26 randomly sampled preparations failed potency specifications, underscoring a real clinical risk [7].

Clinical Evidence: What the Trials Tell Us About Dosing Precision

Correct storage is not a bureaucratic formality. The efficacy signal in the key trials depended on consistent delivery of biologically active peptide.

The Falutz NEJM Trial (2007)

In the randomized, double-blind, placebo-controlled trial by Falutz et al. (N=412), HIV-infected adults with abdominal lipodystrophy received tesamorelin 2 mg subcutaneously once daily or placebo for 26 weeks [4]. The primary endpoint, change in VAT measured by CT scan, showed a mean reduction of 15.2% in the tesamorelin group versus a 5.0% increase in the placebo group (P<0.001) [4]. The authors noted that consistent daily dosing was required to maintain the effect: IGF-1 returned toward baseline within weeks of stopping treatment.

The 52-Week Extension

A 52-week extension of the Falutz trial confirmed that VAT reductions were sustained with continued daily dosing but reversed within 6 months of discontinuation [8]. This time-dependent reversibility underscores why every dose must contain the full 2 mg of active peptide. Degraded drug from improperly stored vials delivers a sub-therapeutic GH stimulus, blunting the VAT response without the patient or clinician necessarily knowing why the effect has diminished.

IGF-1 as a Surrogate Marker of Stability-Related Potency Loss

Because tesamorelin's GH-stimulating effect directly raises IGF-1, serum IGF-1 monitoring provides an indirect check on drug potency in clinical practice. The Endocrine Society's 2011 clinical practice guideline on GH deficiency recommends targeting IGF-1 within the age-adjusted reference range during GH-axis therapy [9]. A patient on correctly stored Egrifta who shows no IGF-1 rise above baseline after 4 to 8 weeks warrants evaluation: first exclude non-adherence, then consider whether storage failure degraded the peptide.

"Serum IGF-1 concentrations should be monitored periodically during tesamorelin therapy to assess both response and potential for adverse effects related to GH excess," according to the Egrifta prescribing information [5].

Mechanism Versus Storage: Why Peptide Integrity Matters

Understanding the mechanism helps clinicians appreciate why storage errors translate directly into efficacy failures.

Peptide Fragility Is Structural

Tesamorelin's N-terminal trans-3-hexenoic acid modification was designed to slow DPP-IV cleavage in vivo, but this modification does not protect the peptide from heat-driven aggregation, freeze-thaw ice-crystal disruption, or UV-induced oxidation in the vial [6]. The peptide's receptor-binding domain spans residues 1 through 29 of the GHRH sequence. Aggregation or truncation of even the first few N-terminal residues abolishes receptor activation because the GHRH receptor requires an intact N-terminus for signal transduction [2].

Deamidation Kinetics at Elevated Temperature

Asparagine residues within GHRH analogues undergo deamidation (conversion to aspartate) at rates that roughly double for every 10°C increase in temperature, following Arrhenius kinetics common to all peptide drugs [6]. A vial left at 37°C (body temperature, as might occur in a pants pocket) for 24 hours accumulates deamidation products at a rate far exceeding what occurs over months at 2 to 8°C. Deamidated tesamorelin retains reduced receptor affinity, so the dose delivered is functionally less than 2 mg even if the mass of peptide is unchanged.

Aggregation and Immunogenicity

Aggregated peptide particles are recognized by the immune system as foreign antigens more readily than soluble monomeric peptide. Anti-tesamorelin antibodies developed in approximately 49% of patients in the Phase 3 trials, though most were non-neutralizing and did not correlate with loss of efficacy [4]. Degraded product from improper storage could theoretically increase immunogenic aggregate load, though this specific hypothesis has not been tested in a prospective trial.

Handling During Travel and Special Situations

Air Travel

Pack Egrifta vials in an insulated medication travel case with ice packs. Keep the medication in carry-on luggage rather than checked baggage, where cargo hold temperatures can drop below 0°C, causing freezing, or spike above 30°C during ground transfers. The Transportation Security Administration (TSA) permits medical liquids and medications in carry-on bags beyond the standard 100 mL limit when declared at the security checkpoint.

Power Outages

If the home refrigerator loses power, the vials must remain cold. A well-insulated refrigerator maintains temperature below 8°C for 4 to 6 hours without power if the door stays closed. Beyond that window, contact the dispensing pharmacy for guidance. Document the excursion duration for pharmacist review before using the vials.

Sharps and Disposal

Used needles and syringes require disposal in an FDA-cleared sharps container [5]. Many U.S. States mandate sharps take-back programs; the FDA provides a locator at SafeMedDisposal.gov. Reconstituted solution remaining after 3 hours should be discarded in the sharps container along with the used needle.

Who Should Not Use Egrifta: Contraindications Relevant to Prescribing

Storage and prescribing decisions overlap. Egrifta is contraindicated in patients with active malignancy, disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor, and in patients with known hypersensitivity to tesamorelin or mannitol (an excipient in the lyophilized powder) [5]. Pregnancy is also a contraindication; tesamorelin is FDA Pregnancy Category X [5]. A prescriber who identifies a contraindication after dispensing should advise the patient not to use and to return vials to the pharmacy for proper disposal.

Monitoring Parameters Tied to Storage and Dosing Accuracy

The following parameters should be tracked to confirm the patient is receiving biologically active drug at the correct dose [5, 9]:

• Serum IGF-1: Check at baseline and at 8 weeks. A rise into the age-adjusted normal range confirms adequate GH stimulation.
• VAT by CT or MRI: Measured at baseline and 26 weeks in trial protocols; often approximated clinically by waist circumference.
• Fasting glucose and HbA1c: GH is diabetogenic. Monitor quarterly, particularly in patients with pre-existing insulin resistance [4].
• Fluid retention signs: Tesamorelin can cause peripheral edema, arthralgias, and carpal tunnel syndrome through IGF-1-mediated sodium retention.

"Patients with diabetes mellitus or glucose intolerance should be monitored carefully because tesamorelin may decrease insulin sensitivity," states the FDA-approved prescribing information [5].